AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies conducted on chronic myeloid leukemia (CML) K562 and KCL22 cell lines demonstrated significant anticancer effects of MOR by suppressing the PI3K/AKT signaling pathway.